Fuller & Thaler Asset Management Inc. Boosts Stock Holdings in LivaNova PLC (NASDAQ:LIVN)

Fuller & Thaler Asset Management Inc. increased its holdings in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 8.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 620,111 shares of the company's stock after purchasing an additional 45,830 shares during the quarter. Fuller & Thaler Asset Management Inc. owned 1.14% of LivaNova worth $28,717,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Artisan Partners Limited Partnership bought a new position in LivaNova in the 4th quarter worth about $21,340,000. Vanguard Group Inc. lifted its position in shares of LivaNova by 12.7% during the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after acquiring an additional 265,291 shares during the last quarter. Capital Research Global Investors increased its stake in LivaNova by 19.1% in the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock worth $74,690,000 after purchasing an additional 258,730 shares in the last quarter. Marshall Wace LLP boosted its stake in LivaNova by 49.2% in the 4th quarter. Marshall Wace LLP now owns 725,593 shares of the company's stock worth $33,602,000 after purchasing an additional 239,227 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in LivaNova during the 4th quarter valued at about $9,645,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Trading Up 0.7 %

Shares of LivaNova stock traded up $0.25 during trading on Monday, reaching $37.51. The company's stock had a trading volume of 507,015 shares, compared to its average volume of 623,166. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company has a market cap of $2.04 billion, a price-to-earnings ratio of 89.31 and a beta of 0.90. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $64.48. The firm's 50-day moving average is $38.94 and its two-hundred day moving average is $46.10.

Wall Street Analysts Forecast Growth

LIVN has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 price target on shares of LivaNova in a research report on Monday, March 17th. Wolfe Research lowered LivaNova from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, February 26th. Stifel Nicolaus decreased their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group reduced their price objective on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research note on Monday, March 3rd. Finally, Mizuho cut their price target on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.